Literature DB >> 17102128

Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia.

Li Yin1, Surender Kharbanda, Donald Kufe.   

Abstract

Resistance of carcinoma cells to hypoxic stress is of importance to the growth of solid tumors. The mucin 1 (MUC1) oncoprotein is aberrantly overexpressed by most human carcinomas; however, there is no known relationship between MUC1 and the hypoxic stress response. The present work has demonstrated that MUC1 attenuates activation of hypoxia-inducible factor-1alpha (HIF-1alpha), a regulator of gene transcription in the response of cells to hypoxic stress. In cells with stable gain and loss of MUC1 function, we have shown that MUC1 up-regulates prolyl hydroxylase 3 (PHD3) expression and promotes HIF-1alpha degradation. PHD activity is attenuated by increases in reactive oxygen species (ROS) generated in the hypoxic stress response. Our results further demonstrate that MUC1 blocks hypoxia-induced increases in ROS and thereby potentiates PHD-mediated HIF-1alpha suppression. Importantly, MUC1 also blocks hypoxia-induced apoptosis and necrosis by suppressing accumulation of ROS. These findings indicate that MUC1 attenuates HIF-1alpha activation in a survival response to hypoxic stress.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102128     DOI: 10.1074/jbc.M610156200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

2.  MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation.

Authors:  Lei Huang; Xiaodong Liao; Michael Beckett; Yuan Li; Kum Kum Khanna; Zhugang Wang; Surender Kharbanda; Ralph Weichselbaum; Donald Kufe
Journal:  Genes Cancer       Date:  2010-03

3.  MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells.

Authors:  Li Yin; Zekui Wu; David Avigan; Jacalyn Rosenblatt; Richard Stone; Surender Kharbanda; Donald Kufe
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

4.  Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.

Authors:  Deepak Raina; Rehan Ahmad; Maya Datt Joshi; Li Yin; Zekui Wu; Takeshi Kawano; Baldev Vasir; David Avigan; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

Review 5.  MUC1 and colorectal cancer pathophysiology considerations.

Authors:  Yaron Niv
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

6.  MUC1 oncoprotein is a druggable target in human prostate cancer cells.

Authors:  Maya Datt Joshi; Rehan Ahmad; Li Yin; Deepak Raina; Hasan Rajabi; Glenn Bubley; Surender Kharbanda; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

7.  MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway.

Authors:  Deepak Raina; Rehan Ahmad; Dongshu Chen; Shailendra Kumar; Surender Kharbanda; Donald Kufe
Journal:  Cancer Biol Ther       Date:  2008-12-09       Impact factor: 4.742

8.  MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8.

Authors:  Naoki Agata; Rehan Ahmad; Takeshi Kawano; Deepak Raina; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 9.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

10.  Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer.

Authors:  N Khodarev; R Ahmad; H Rajabi; S Pitroda; T Kufe; C McClary; M D Joshi; D MacDermed; R Weichselbaum; D Kufe
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.